Market overview:
Adjuvant is formulated as a part of vaccine to induce protection against infection in human beings. Adjuvant has become an important ingredient to be used in some vaccines which help in creating stronger immune response in an individual receiving the vaccine.
Growing prevalence of infectious diseases such as HIV (Human Immunodeficiency Virus), HPV (Human Papillomavirus), tuberculosis and caner diseases has given positive impact on target market growth. Further, rising use of synthetic & recombinant vaccines and ongoing clinical trials in development of vaccines is anticipated to accelerate the demand for Vaccine Adjuvant market growth over the forecast period.
Key Highlights:
- In April 2023, new ‘R21/Matrix-M’ malaria vaccine developed by University of Oxford and manufactured by Serum Institute of India Pvt. Ltd.(SIIPL), with leveraging adjuvant technology of Novavax’s has received licensed with regulatory clearance for its use in Ghana by Food and Drugs Authority (FDA Ghana).
Click Here to Get PDF Brochure of this Report:
https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/86
Analyst View:
Growing prevalence of diseases across globe has become a leading factor in target market growth. Further, increased favorable government policies for immunization of an individual against serious diseases across globe is likely to propel market growth. Furthermore, presence of major players and continuous research & development activities in developed countries is expected to fruitful the demand for Vaccine Adjuvant market growth in coming years.
Report Scope:
| Attribute | Details |
| Base year for estimation | 2020 |
| Forecast period | 2020 – 2030 |
| Market representation | Revenue in USD Million & CAGR from 2020 – 2030 |
| Market Segmentation | By Product Type : Particulate Adjuvants, Emulsion Adjuvants, Pathogen Adjuvants, Combination Adjuvants, and Other Adjuvants
By Route of Administration : Oral, Intranasal, Intramuscular, Subcutaneous, Intradermal, and Others By Disease Type : Cancer, Infectious Disease, and Others By Application : Research, Commercial, and Others |
| Regional scope | North America – U.S., Canada
Europe – UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific – Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America – Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa – South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
Key players:
- SEPPIC Inc.
- Novavax
- Hayashibara
- SPI Pharma Inc
- Invivogen
- Avanti Polar Lipids, Inc.
- MPV Technologies
- OZ Biosciences
- Agenus,Inc.
- Brenntag Biosector
- Spectrum Pharmaceuticals. Inc.
- Sigma Aldrich
- Adjuatis
- Vaxliant
- Adjuvance Technologies, Inc.
- GlaxoSmithKline plc.
- Puma Biotechnology
- Tj Kaiwei
- Zhouyue
- Aphios
- CSL Limited.
Ask for a sample copy of this report at
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/86
Key questions of Vaccine Adjuvant Market:
- What is the current global market size of vaccine adjuvants, and what is the projected growth rate over the next few years?
- What are the different types of vaccine adjuvants available in the market, and how do they enhance the immune response to vaccines?
- How are advancements in vaccine development and research driving the demand for novel and more effective adjuvants?
- What are the key regulatory considerations and approvals necessary for vaccine adjuvants, and how do they impact market entry?
- Which vaccines and vaccine candidates are utilizing adjuvants, and what are the specific indications they target?
- How do vaccine adjuvants contribute to improving vaccine efficacy, durability of protection, and overall vaccine safety?
- What are the primary challenges associated with the development and commercialization of vaccine adjuvants?
Conclusion:
In conclusion, the vaccine adjuvant market is a vital component of modern healthcare, playing a pivotal role in enhancing the efficacy and effectiveness of vaccines.
Browse More Related Reports:
- Diagnostic Labs Market : accounted for US$ 354.3 billion in 2022 and is estimated to be US$ 919.4 billion by 2032 and is anticipated to register a CAGR of 9.4%.
- Oncology Molecular Diagnostics Market : accounted for US$ 3.67 billion in 2022 and is estimated to be US$ 18.2 billion by 2032 and is anticipated to register a CAGR of 16.4%.
- Breast Cancer Diagnostics Market : accounted for US$ 4.5 billion in 2022 and is estimated to be US$ 9.10 billion by 2032 and is anticipated to register a CAGR of 7.5%.